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Abstract  
Background: Pain is one of the most common and troublesome non-motor symptoms of 
Parkinson’s disease; it can appear at any time during the disease, and it is often present 
before diagnosis. However, there is little or no consensus on its definition.  
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Methods: An expert group of clinicians with relevant research experience met to review the 
existing evidence, and to identify gaps in our understanding towards an optimized therapy of 
pain in Parkinson's disease. 
 
Results: Key findings from epidemiologic, neurophysiologic, neuroimaging and clinical 
studies are reviewed. In each case, the evidence base is limited by wide variations in the 
definitions of pain applied, study methodologies and populations evaluated. 
 
Conclusions: Disease-related as well as medical conditions trigger spontaneous pain in 
Parkinson patients which is then abnormally processed and results in painful manifestations 
in specific body parts. Dopaminergic medications like rotigotine as well as opiate analgesics 
like oxycodone have shown positive results but future studies with more detailed pain 
characterization at inclusion are warranted.  
 
Introduction 
Although pain has long been acknowledged as a feature of PD [1], it remains an under-
diagnosed and under-treated symptom. When present, pain negatively impacts the quality of 
life [2] and survey’s evaluating patient perceptions of their most bothersome symptoms 
consistently find that pain ranks high in all stages of the disease [3, 4]. 
 
A key reason for the lack of recognition and under-treatment is the difficulty in defining and 
characterizing pain in PD. Different studies have categorized pain in several ways including: 
PD (including fluctuation-related, dyskinesia-related and central pain) vs. non-PD related 
pain [5-7]; primary (CNS) vs. secondary (musculoskeletal system) pain [8]; nociceptive vs. 
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neuropathic, chronic vs. acute, and pain in different body parts [9]. Several experts have 
tried to better define the clinical features and taxonomy of pain in PD [10,11]. Clinically it is 
important in PD to distinguish pain arising from dystonic posture (dystonic pain) from pain 
localized in body parts unaffected by dystonia (non-dystonic pain) and secondary to 
musculoskeletal, peripheral or central neuropathic pain. [6]  
 
To address this issue, an expert group of clinicians reviewed the existing evidence to identify 
gaps in our understanding towards an optimized therapy of pain in PD. This article reviews 
the findings of the main research approaches (epidemiology, neurophysiology, imaging and 
clinical research) to evaluate what insights they can offer to better define and characterize 
pain in PD. A full list of references is provided in the supplementary materials.  
 
Epidemiologic research 
Studies in PD have consistently shown that pain can appear at any time during the disease 
[12], often before diagnosis [13] and its prevalence is higher than controls (Table 1) [7,15-
20]. Most recently, the validation of the King’s Parkinson’s disease Pain Scale (KPPS) study 
showed higher KPPS total score in PD patients versus age and sex matched controls mostly 
in the domains of musculoskeletal, chronic, fluctuation-related, nocturnal, orofacial, and 
radicular pain [21]. 
 
The wide range of results can largely be explained by the heterogeneity of pain types 
studied and lack of objective outcome measures. Added to this complexity are the various 
painful co-morbidities, such as arthritis and muscular-skeletal deformities that often co-exist 
in elderly PD [20-22]. Patients may also have different combinations of pain types at the 
same time and the presence of depression (common in PD) is well known to associate with 
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higher pain sensitivity [7,18]. Indeed, even studies showing no absolute difference in pain 
prevalence revealed that after adjustments for osteoarticular comorbidity, PD patients are 
twice as likely to suffer from chronic pain than age-matched non-PD control [7].  
 
They are also more likely to receive prescription of analgesics than the general population 
(82% vs 77%), including medications for chronic use (33 vs 20%) like opiates, 
acetaminophen [23]. 
 
Neurophysiology  
In the last decade, several neurophysiology and neuroimaging studies have provided useful 
information on nociceptive input processing (evoked pain) mechanisms in PD and 
investigated pain threshold and pain tolerance using different kinds of stimulation (e.g. 
electrical, thermal, laser stimuli) [24-35], nociceptive withdrawal reflex (NWR) [24,36,37] and 
scalp laser evoked potentials (LEPs) [29-32, 38]. Pain threshold is defined as the minimum 
intensity of stimulation at which subjects report a change in sensation from unpainful to 
faintly painful and evaluates the sensory-discriminative component, while pain tolerance is 
defined as the minimum intensity of stimulation perceived as an intolerable painful sensation 
and assesses the affective and cognitive dimension [39-40]. By contrast, the NWR following 
electrical stimulation of the sural nerve explores pain processing in the spinal cord [41-43] 
and LEPs recordings are used to non-invasively assess the functional status in some 
cerebral structures (the cingulate gyrus and insula) responding to nociceptive inputs [44-46]. 
 
To date, PD patients have been enrolled under different types of chronic dopaminergic 
treatment rather than drug naïve (Table 2) and presented a decreased pain 
threshold/tolerance to various stimuli, a reduced NWR threshold to electrical stimuli and 
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changes in N2/P2 LEP amplitude [25, 27, 28, 31, 32, 35, 47, 48]. These abnormalities point 
to increased activity in both the ascending lateral and medial pain pathways [49]. Although 
peripheral mechanisms may also contribute, and several skin biopsy studies investigating 
small fibers or terminal endings have documented cutaneous denervation [50-52], recent 
studies have indicated that their role is not as important as central mechanisms to abnormal 
pain processing [38]. Indeed, neurophysiologic studies in PD patients with different kinds of 
pain including muscoloskeletal, peripheral or central neuropathic have shown abnormalities 
of nociceptive input processing at both spinal and cortical level [31,32]. 
 
Moreover, lack of correlation between pain-processing abnormalities and intensity/quality of 
pain does not support an exclusive relationship. Although some observations suggest that 
spontaneous pain is associated with additional changes in nociceptive processing 
mechanisms [Schestatsky et al. 2007; Tinazzi et al. 2010], the majority of the studies 
indicate that similar changes in central pain processing intervene in patients with PD with 
and without pain. [29,31,32,35,47]. 
 
In summary, in PD disease-related (e.g. motor complications, dystonia, marked rigidity or 
bradykinesia) as well as medical conditions (e.g. osteoporosis, rheumatic disease) trigger 
spontaneous pain which is then abnormally processed and results in painful manifestations 
in specific body parts [53].  
 
Neuroimaging 
Functional neuroimaging techniques have contributed to expand our understanding of the 
neural basis of pain [54]. The consensus is there is no single ‘pain center’ but instead a 
complex ‘pain matrix’ including (but not limited to): thalamus, amygdala, hypothalamus, 
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insula, primary and secondary somatosensory cortexes (S1 and S2), primary motor cortex 
and anterior and posterior cingulate cortexes. The basal ganglia play a crucial link between 
pain and the emotional experience through what is collectively known as the ‘salience 
network’. The salience network is an intrinsically connected large-scale network anchored in 
the anterior insula and dorsal anterior cingulate cortex, and includes three key subcortical 
structures: the amygdala, the ventral striatum, and the substantia nigra/ventral tegmental 
area [55]. Several studies have shown that chronic pain shifts salience network activity 
[55,56], while other studies have indicated that in PD activity of the salience network is 
affected by cognitive and motor dysfunction [57-59]. 
PD patients tested in the OFF’ state, were found to have significantly increased cortical pain-
induced activation (characterized by increased regional cerebral blood flow) in the ipsilateral 
prefrontal cortex, ipsilateral insula, and contralateral anterior cingulate in comparison with 
the control group [27]. These observations suggest presence of an abnormal pain-induced 
activation in two main pathways, the sensory discriminative processing (mediated via the 
insula) and the affective motivational processing (medicated by the anterior cingulate cortex 
and prefrontal cortex) [27]. In another imaging study by the same group, significant 
correlations between [123I]-FP-CIT binding to dopamine transporters and subjective heat 
pain threshold were shown in the posterior cingulate cortex and insula (i.e. extrastriatal 
areas). By contrast, there was no correlation between striatal dopamine transporter binding 
and pain threshold - suggesting that pain perception abnormalities in PD may not be directly 
related with striatal dopaminergic dysfunction but could perhaps reflect extrastriatal 
dopaminergic dysfunction, with an imbalance between the sensory and the affective cerebral 
nociceptive pathways [60]. Such findings are supported by another study using multimodal 
imaging techniques which demonstrated significant thinning in several cortical regions in PD 
with persistent versus those without pain and highlighted the contribution of frontal, 
prefrontal and insular areas in nociceptive modulation and accumbens-hippocampus 
disconnection [61]. 
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In one of the few specific fMRI studies, Tan et al combined resting state and pain-stimuli-
induced task state fMRI to identify alterations in functional connectivity related to pain in PD 
[59]. Compared with controls, PD patients showed decreased functional connectivity in the 
putamen during evoked pain (51°C heat pain stimuli) as well as decreased functional 
connectivity in the salience network and the sensorimotor network during the rest state. 
They found that functional network connectivity between the basal ganglia and the salience 
network are reduced during both states in PD. In addition, the right frontoparietal network 
was significantly disturbed during evoked pain [59]. 
 
Impact of dopaminergic medication on pain and pain processing mechanisms 
Several studies using different methodologies have investigated the influence of 
dopaminergic medication on pain in PD. As before, these studies have enrolled patients 
under chronic dopaminergic treatment rather than drug-naive patients, and so comparisons 
are limited to differences between the ON and OFF states. 
 
While no correlation has been found between spontaneous pain and daily levodopa dose, 
some studies have reported that pain of variable quality and localization (muscular pain, 
pain associated with degenerative osteoarticular changes, and oral or genital pain) may 
fluctuate in intensity during OFF and ON states [62, 63], particularly in presence of 
dyskinesia [34]. This is supported by several uncontrolled observations, which indicate that 
spontaneous pain may be minimized by strategies like continuous dopaminergic release 
and stimulation (e.g. apomorphine/levodopa infusion, and deep brain stimulation) that 
usually improve levodopa-related motor complications [64-69]. However, owing to the lack 
of a placebo group these observations need to be considered with caution.  
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With regards to the impact of levodopa on evoked pain, there have been several conflicting 
studies, possibly due to differences in study designs, patient selection and pain types that 
had been investigated. Acute levodopa challenges have found either no effect or have 
shown that levodopa normalizes the decreased pain threshold observed in PD patients [24-
27, 30, 65, 70]. In one study, acute levodopa medication in an otherwise chronically treated 
patient group increased the NWR threshold to electrical stimuli in pain-free PD patients [24], 
but a later study failed to confirm this finding [25]. These variable results may reflect 
methodological issues, placebo effect or other confounding factors, including the presence 
of levodopa-induced motor complications and suggest involvement of neurotransmitter other 
than the dopaminergic system. For example, when comparing the levodopa-induced change 
in cold pain threshold and tolerance among stable responders, fluctuators without and with 
dyskinesia, threshold increase was larger in dyskinetic patients and in fluctuators than in 
stable patients [34]. However, all previous studies dealing with levodopa-induced changes in 
pain thresholds failed to specify whether patients were stable levodopa responders, 
fluctuators, or had dyskinesia. Of note, the studies which did find a significant levodopa 
effect on pain thresholds typically enrolled patients with a long disease duration and under 
chronic dopaminergic therapy, and we can therefore assume they included some with motor 
complications [24-27]. This includes neuroimaging studies showing that levodopa 
administration increases pain thresholds to cold water test and reduces pain-induced 
nociceptive cerebral areas activation in both pain-free PD and in PD patients with 
neuropathic pain [27,28]. 
 
Thus, there is evidence that levodopa directly modifies pain thresholds, favoring 
dopaminergic system involvement. However, neuroimaging studies of acute apomorphine 
challenges have found that direct dopamine receptor stimulation with apomorphine has no 
effect on electrical and heat-pain thresholds or as compared with placebo in pain-free PD 
patients [33]. The differences between the dopamine precursor levodopa and apomorphine 
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suggest that the impact of levodopa on pain thresholds may, at least in part, be mediated 
by other monoaminergic systems such as noradrenaline. Indeed, all the key thalamic and 
midbrain nuclei identified as being involved in the so-called ‘pain matrix’ [71,72], are 
directly or indirectly affected in PD implying involvement of non-dopaminergic pathways 
including noradrenergic and serotonergic transmission. 
Clinical trials  
There has been a disparate range of poor quality clinical trials evaluating pain in PD, with 
significant differences in the types of pain considered, and methodologies. Taken 
collectively, the studies have been underpowered to assess pain, have not used relevant 
comparator groups and many have been open-label. Lack of homogeneous pain definitions 
have not only led to important differences in inclusion and exclusion criteria, but also in the 
pain outcomes measured. Moreover, correct characterization of nociceptive and neuropathic 
pain is an important basis for treatment decision. 
Neurophysiology studies in patients who have undergone DBS have been more consistent 
than those conducted with levodopa, with most studies showing increased heat pain 
threshold in PD patients with and without pain [65,68,73]. Subjective improvement in PD-
related pain has been documented also after pallidotomy [74,75], and DBS of the globus 
pallidus [66] and subthalamic nucleus [65,76] in advanced PD, and therefore lend further 
support to the role of the basal ganglia in modulating pain. Of note, the study by Kim et al 
[76] asked DBS candidates to rate the severity of their pain in each body part. Of the 23 
patients reporting pain, 20 (87%) showed pain improvement after 3 months. Eighteen 
patients described fluctuation-related pain at baseline, and of these 12 reported a decrease 
in, and 5 complete disappearance of OFF pain. Of the 4 patients with non-fluctuating 
preoperative pain, 2 reported improvement, however new pain was reported to develop in 
many patients during the 3-month follow-up, suggesting that the study captured a mixture of 
OFF-related pain and other pain types [76].  
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The idea that PD pain associated with motor fluctuations may be minimized by continuous 
dopaminergic strategies was first assessed in the RECOVER study, which evaluated non-
specified pain as an exploratory outcome in a subpopulation of PD patients who had 
nocturnal/early morning problems, and reported improvements in pain using a Likert scale 
with rotigotine compared with placebo [77,78]. More recently, the DOLORES study was the 
first double-blind placebo-controlled study to investigate the effect of a dopamine agonist 
(rotigotine) on PD-associated pain [79]. Although the DOLORES study was underpowered to 
observe statistical differences, it did show a general improvement in PD-associated pain 
intensity for rotigotine versus placebo (numerical difference of 0.76 Likert points). 
Unfortunately, because the Likert scale assesses pain severity as a composite of all types of 
PD pain, it was not possible to determine which pain type drove the improvement. However, 
the treatment effect appeared to be numerically greater in the subgroup of patients with 
‘fluctuation-related’ pain (1.07 Likert points) [79]. This is in line with the efficacy of rotigotine 
in managing the symptoms of wearing-off and suggests an indirect effect of pain 
improvement secondary to motor improvement [36,80]. 
 
Other than this, there is scant clinical trial data on the pain response to the other currently 
available PD medications. An exploratory post-hoc analysis analyses of pooled data from 
safinamide trials has shown significantly reduction in the number of concomitant pain 
treatments vs. placebo [81]. Another open-label study in 14 patients has reported that 
continuous levodopa infusion with the levodopa intestinal gel had ‘good’ effects on severe 
nocturnal dystonic pain, but the outcome measures used to assess this aspect were not 
reported [82]. 
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Taking into consideration that not all PD pain may be dopaminergic mediated, one open-
label, 6-week study evaluated the efficacy of the serotonin and norepinephrine reuptake 
inhibitor duloxetine in PD patients with painful phenomena. Thirteen of the 20 PD patients 
who completed the study reported varying degrees of pain relief, with significant 
improvements in pain visual analog scales, brief pain inventory (BPI) and the Short-Form 
McGill Pain Questionnaire. However, there was no change in pain threshold after treatment 
[83]. 
 
Finally, the efficacy and safety of opiate analgesics has been studied in PD patients 
experiencing chronic pain. These types of study had previously been avoided due to 
concerns about the use of opiates in PD due to the risk of aggravating constipation as well 
as inducing somnolence, confusion and worsening cognition. However, the combination of 
oxycodone with the peripheral opiate antagonist naloxone (in a fixed ratio of 2:1) minimizes 
the risk of constipation [84] and opens the possibility of using this drug to treat PD pain. In 
favor of this approach, one small observational study showed significant pain relief as 
assessed by reductions in numeric rating scales and in BPI scores [85]. Moreover, no 
significant changes were observed in bowel function and constipation symptoms over the 8-
week study period. 
 
To test this approach further, the PANDA study was a large double-blind placebo controlled 
randomized study which recruited patients with at least one type of severe pain, and an 
average 24-hour pain score of at least 6 out of 10 (on an 11-point pain scale). Although the 
primary endpoint (24-hour pain score at week 16) was not significant, assessments of 24-
hour pain at other time-points during the study and other secondary endpoints (responder 
rates for 24-hour pain scores) favored treatment with oxycodone–naloxone [86]. In addition, 
subgroup analyses demonstrated potential added benefit to patients from severe 
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musculoskeletal or nocturnal pain types. As the first trial of its kind, the methods in this study 
were exploratory, and many lessons can be learned. The study was enriched for patients 
with severe pain, but patients are unlikely to tolerate severe pain for more than a few weeks, 
which might explain the dropout rate and large number of missing data at 16 weeks and 
regression to the mean in both the opiate and placebo treatment arms after 16 weeks. The 
authors of the study also suggested that assessment of change in less severe pain might 
have better represented the treatment effect. Interestingly the maximum dose allowed in the 
study was in the low range of that used in chronic pain patients. Given the good safety 
profile and the limited increased risk of constipation and nausea in the PD cohort treated 
with active drug, future studies could consider the use of higher doses particularly in younger 
patients. Another important study limitation was the use of levodopa as rescue medication, 
which might have confounded assessment on some types of PD-related pain [86]. The study 
also showed a large placebo response, which is a problem in pain research because 
expectation and previous experience are both well-established key mediators of both 
placebo and nocebo effects [87], and indeed for pain itself. Systematic reviews of chronic 
pain trials have shown that a substantial proportion of the beneficial and adverse effects of a 
drug is attributable to placebo [88-90]. 
What next? 
Bringing together the various research angles we can conclude that pain is a common 
feature of PD, and PD patients experience more pain than age-matched controls. 
Accumulating evidence supports the concept that in PD pain etiology is multifactorial 
although musculoskeletal pain seems far more frequent than disease-related pain, at least in 
patients with severe complaints. Specific brain connectivity and structural abnormalities are 
present in PD patients likely resulting from changes in the processing of central and 
peripheral nervous system painful stimuli. In specific cases this maybe aggravated by the 
presence of skeletal deformities and other various co-morbidities a PD patient may also 
suffer [91]. 
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Considering all the limitations observed in previous clinical trials the need for a widely 
accepted definition of pain in PD is obvious. Moving forward, it is essential that studies 
should be adequately powered, recruit patients experiencing the types of pain that can be 
targeted by the proposed mechanism of action of the intervention and employ relevant 
controls and outcomes measures [92]. As a construct, pain is difficult to assess – there is no 
unit for measurement as it is a subjective experience and each person’s interpretation of 
pain will differ based on past experiences and expectations. Use of validated pain scales will 
aid enrichment of the clinical population for tailored therapy based on the type of PD pain. At 
present, the KPPS [21] is the only scale validated for use in PD and is now being used by 
several investigators. The scale is likely to evolve with use, and can be complemented in 
future trials with other scales.  
 
It will be important to further clarify the role of the dopaminergic system in modulating pain. It 
may also be interesting to understand why pain is more common in PD, than in atypical 
parkinsonian disorders like MSA, PSP and corticobasal degeneration [93]. The influence of 
genetic variants of the COMT enzyme, which are associated with different responses to 
acute and chronic pain [94,95] also merits further evaluation. Considering non-dopaminergic 
mechanisms will also be important. For example, the efficacy of certain antidepressants and 
antiepileptic drugs warrants testing [92]. Likewise, although there has been one small open-
label study with duloxetine [83], the influence of the noradrenergic system certainly requires 
further study. Finally, since use of over the counter non-steroidal analgesics is so high in PD 
[23], there is an urgent need to evaluate which types of pain (if any) they improve.   
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Management of pain in clinical practice 
From the management perspective, it is currently impossible to give firm advice based on 
the paucity of compelling evidence. Most neurologists treat patients with chronic pain, but 
few have received any training in this area, underscoring a clear educational need. 
Nevertheless, is frequently under-recognized and often not reported by patients, and 
because it can have such an impact of daily quality of life – it is incumbent on clinicians to 
investigate about its presence and assess it in relation to the whole spectrum of non-motor 
symptoms [96,97]. Clinicians should try to understand what type of pain the patient is 
suffering because the underlying mechanisms and treatment options vary. While fluctuation-
related pain may respond to adjustments in dopaminergic therapy or DBS, dystonic pain to 
botulinum toxin injections and central pain may respond to centrally pain-modulating 
medications. Certainly, the good response of some pains to dopaminergic medication means 
that clinicians should ensure that the patients current dopaminergic therapy is optimized 
[98].  
 
Non-pharmacologic approaches may also be of benefit. The benefits of physiotherapy for 
pain are increasingly accepted with increasing evidence that physiotherapy consistently 
reduces self-reported pain in adults suffering from a variety of painful conditions [99]. 
Musculoskeletal pain in PD often relates to camptocormia and lumbar spine syndromes, 
similar to the majority of elderly in the general population. All methods (such as physical 
therapy, warming -up and stretching) used to treat these painful conditions can be applied in 
PD patients. Other systematic reviews have suggested that patients with chronic pain will 
benefit from around 150 min of moderate equivalent physical activity per week [100]. It is 
also important to consider secondary causes of pain – for example painful leg edema may 
indicate switching antiparkinsonian medication, and abdominal pain could indicate that the 
patient is suffering from constipation. Comorbidities should be considered, as pain can often 
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be attributed to a non-PD causes including arthritis, diabetes and cancer. If pain is severe 
despite optimizing dopaminergic therapy, one can consider therapy with low dosages of 
prolonged release oxycodone/naloxone [80]. 
 
We hope this review draws attention to the limitations of published studies and the difficulties 
in developing guidelines based on the findings so far. There is an urgent need for consensus 
on what constitutes PD pain. Clarity in this area will undoubtedly lead to better designed 
studies. 
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Table legends 
 
Table 1: Prevalence of pain estimates from epidemiological studies including a control group 
Table 2: Results from neurophysiology studies evaluating pain thresholds in PD patients 
under OFF conditions.  
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Table 1 
 
 
Study Pain type PD patients 
with pain 
N (%) 
Control 
subjects with 
pain 
N (%) 
P 
value 
Chaudhuri et al 
[14] 
All pain 27% 30% 0.6 
Etchepare et al 
[15] 
Back pain 104 (60%) 100 (23%) <0.001 
Broetz et al [16] Back pain 101 (74%) 132 (27%) <0.001 
Negre-Page et al 
[7] 
Chronic pain 
(all types) 
450 (61%) 98 (58%) 0.74 
Defazio et al [20] All pain 402 (70%) 317 (63%) 0.04 
Beiske et al [17] All pain 176 (83%) Norwegian 
population (30%) 
<0.001 
Ehrt et al [18] All pain 227 (67%) 100 (39%) <0.001 
Madden and Hall 
[19] 
Shoulder 
pain 
25 (80%) 25 (40%) 0.006 
Chaudhuri et al 
[21] 
Seven types 
of pain 
validated in 
the KPPS 
N=178 
Mean ±SD 
KPPS total 
score: 
25.2 ±22.1 
N=83 
Mean ±SD  
KPPS total 
score: 
9.34 ±12.5 
 
<0.026 
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Table 2 
 
Study PD patients with 
pain vs. healthy 
controls 
Pain free PD 
patients vs. 
healthy controls 
PD patients with 
pain vs. PD 
patients without 
pain 
Pain threshold to mechanical stimuli 
de Andrade D et al, 2012 
[73] 
- Reduced threshold - 
Pain threshold to electrical stimuli 
Gerdelet Mas et al, 2007 
[24] (musculoskeletal 
pain) 
- Reduced threshold - 
Mylius et al, 2009 [26] Reduced threshold Reduced threshold Similarly reduced 
threshold 
Zambito Marsala et al, 
201135 (musculoskeletal 
pain & peripheral 
neuropathic pain) 
Reduced threshold 
 
Reduced threshold Similarly reduced 
threshold 
 
Perrotta et al, 2011 [25] - Reduced threshold - 
Pain threshold to cold water 
Brefel-Courbon et al, 2005 
[27] 
- Reduced threshold - 
Lim et al, 200834 Reduced threshold - - 
Brefel-Courbon et al, 2013 
[28] (primary central pain) 
Reduced threshold 
 
Reduced threshold Similarly reduced 
threshold 
Pain threshold to heat thermode 
Djaldetti et al, 2004 [47] 
(primary central pain) 
Reduced threshold 
 
Reduced threshold Lower threshold in 
patients with pain 
Schestatsky et al, 2007 
[29] (primary central pain) 
Reduced threshold 
 
Reduced threshold Lower threshold in 
patients with pain 
 
Mylius et al, 2009 [26] 
(musculoskeletal pain) 
Normal threshold 
 
Normal threshold Similar threshold 
 
Dellapina et al, 2011 [33] - - Similar threshold- 
Nandhagopal et al, 2010 
[48] 
- Normal threshold - 
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Pain threshold to laser CO2 
Schestatsky et al, 2007 
[29] (primary central pain) 
Reduced threshold 
 
Normal threshold Lower threshold in 
patients with pain 
 
Tinazzi et al, 2008 [30] - Reduced threshold - 
Tinazzi et al, 2009 [31] - Reduced threshold - 
Tinazzi et al, 2010 [32] - Reduced threshold - 
Pain threshold to electrical stimuli 
Zambito Marsala et al, 
2011 [35]  
(musculoskeletal pain & 
peripheral neuropathic 
pain) 
Reduced threshold 
 
Reduced threshold Similarly reduced 
threshold 
 
Nociceptive withdrawal reflex threshold 
Gerdelet Mas et al, 2007 
[24] 
- Reduced threshold - 
Perrotta et al, 2011 [25] - Reduced threshold - 
Mylius et al, 2011 [37] 
(musculoskeletal pain) 
Reduced threshold 
 
- - 
Laser evoked potentials 
Tinazzi et al, 
2008/2009/2010 [30-32] 
(musculoskeletal pain) 
Reduced N2/P2 
amplitude 
Reduced N2/P2 
amplitude 
Lower N2/P2 
amplitude in 
patients with pain 
Schestatsky et al, 2007 
[29] 
Increased N2/P2 
amplitude (primary 
central pain) 
Normal N2/P2 
amplitude 
Increased N2/P2 
amplitude in 
patients with pain 
Zambito Marsala et al, 
2017 [38] 
- Reduced N2/P2 
amplitude 
- 
 
 
 
 
